A Natural Protein for Reversing Metabolic Disorders

OVERVIEW

This invention addresses a novel therapeutic target protein to reverse metabolic disorders. This protein is a binding protein that interacts either individually or in combination with several families within the fibroblast growth factors (FGF) that are involved in the regulation of metabolism. Preclinical studies with murine models have demonstrated that this protein plays a pivotal role in lowering blood glucose levels, reversing fat accumulation, and reducing body weight.

BACKGROUND

According to the World Health Organization, metabolic diseases such as obesity and type 2 diabetes are becoming a major global health issue as there are an increasing number of diagnosed patients annually. This invention can bring innovative targeted treatment plans for patients with metabolic diseases.

Benefit

• Specifically targets and lowers blood glucose levels, offering a precise approach to managing hyperglycemia in diabetic patients
• Novel therapeutic strategy by utilizing FGFBP3, expanding the range of available treatments for diabetes and hyperglycemia
• Might present fewer side effects compared to some traditional diabetes medications, potentially reducing risks associated with chemical drug therapies
• Provide insights to certain cellular signaling pathways for future inventions related to metabolic diseases.

Market Application

• Drug Development: The protein could be used as a drug treatment method to reverse disorders that are associated with metabolic syndromes such as fatty liver disease, type 2 diabetes, insulin resistance, and glucose intolerance. Also has its pharmaceutical benefits in that there are various routes of administration available including oral and parenteral methods.

• Biotechnology:Can be applied to new biotechnology for novel diagnostics and treatments regarding metabolic disorders that are known to be challenging such as obesity.
• Oncology: Target for oncology treatments for cancers that potentially develop from metabolic disorders such as hepatocellular carcinoma (HCC), colon cancer, and pancreatic cancer.

Publications

Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism.Sci Rep
8, 15973 (2018). https://doi.org/10.1038/s41598-018-34238-5

Intellectual property status

Granted Patent

Patent number : Patent No. 9,789,160

Where : USA